Potential role of mesenchymal stromal cells in pancreatic islet transplantation

Transplantation Reviews

Volumn 27, Issue 1, 2013, Pages 21-29

  Hematti, Peiman ^a   Kim, Jaehyup ^a   Stein, Andrew P ^a   Kaufman, Dixon ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN;

CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DIABETIC PATIENT; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HISTORY OF MEDICINE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MESENCHYMAL STROMA CELL; MOLECULAR PATHOLOGY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; REVIEW; TISSUE REGENERATION; TISSUE REPAIR;

EID: 84873570068     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2012.11.003     Document Type: Review

References (101)

1. Ding Y., Bushell A., Wood K.J. Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation. Transplantation 2010, 89:270-273.
2. Balamurugan A.N., Bottino R., Giannoukakis N., Smetanka C. Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas 2006, 32:231-243.
3. Vija L., Farge D., Gautier J.F., et al. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab 2009, 35:85-93.
4. Atkinson M.A., Maclaren N.K. The pathogenesis of insulin-dependent diabetes mellitus. N Eng J Med 1994, 331:1428-1436.
5. Oldstone M.B. Molecular mimicry and immune-mediated diseases. FASEB J 1998, 12:1255-1265.
6. Silverstein J., Klingensmith G., Copeland K., et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005, 28:186-212.
7. Parving H.H., Hommel E., Mathiesen E., et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988, 296:156-160.
8. Powers A.C. Insulin therapy versus cell-based therapy for type 1 diabetes mellitus: what lies ahead?. Nat Clin Pract Endocrinol Metab 2008, 4:664-665.
9. Kelly W.D., Lillehei R.C., Merkel F.K., Idezuki Y., Goetz F.C. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967, 61:827-837.
10. White S.A., Shaw J.A., Sutherland D.E. Pancreas transplantation. Lancet 2009, 373:1808-1817.
11. Nanji S.A., Shapiro A.M. Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab 2006, 8:15-25.
12. Kemp C.B., Knight M.J., Scharp D.W., Lacy P.E., Ballinger W.F. Transplantation of isolated pancreatic islets into the portal vein of diabetic rats. Nature 1973, 244:447.
13. Scharp D.W., Murphy J.J., Newton W.T., Ballinger W.F., Lacy P.E. Transplantation of islets of Langerhans in diabetic rhesus monkeys. Surgery 1975, 77:100-105.
14. Brendel MD HB, Schultz AO, Bretzel RG International islet transplant registry newsletter 8. 2000:1-20.
15. Linetsky E., Bottino R., Lehmann R., Alejandro R., Inverardi L., Ricordi C. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 1997, 46:1120-1123.
16. Lakey J.R., Warnock G.L., Shapiro A.M., et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 1999, 8:285-292.
17. Shapiro A.M., Lakey J.R., Ryan E.A., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Eng J Med 2000, 343:230-238.
18. Ryan E.A., Paty B.W., Senior P.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
19. Moberg L., Johansson H., Lukinius A., et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039-2045.
20. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Eng J Med 2006, 355:1318-1330.
21. CITR coordinating center TEC. Collaborative Islet Transplant Registry Sixth Annual Report. In., 2009: 1-10.
22. Onaca N., Naziruddin B., Matsumoto S., Noguchi H., Klintmalm G.B., Levy M.F. Pancreatic islet cell transplantation: update and new developments. Nutr Clin Pract 2007, 22:485-493.
23. Shapiro J. Eighty years after insulin: parallels with modern islet transplantation. CMAJ 2002, 167:1398-1400.
24. Langer R.M. Islet transplantation: lessons learned since the Edmonton breakthrough. Transplant Proc 2010, 42:1421-1424.
25. de Kort H., de Koning E.J., Rabelink T.J., Bruijn J.A., Bajema I.M. Islet transplantation in type 1 diabetes. BMJ 2011, 342:d217.
26. Robertson R.P. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010, 59:1285-1291.
27. Harlan D.M., Kenyon N.S., Korsgren O., Roep B.O. Current advances and travails in islet transplantation. Diabetes 2009, 58:2175-2184.
28. Khan M.H., Harlan D.M. Counterpoint: clinical islet transplantation: not ready for prime time. Diabetes Care 2009, 32:1570-1574.
29. Naftanel M.A., Harlan D.M. Pancreatic islet transplantation. PLoS Med 2004, 1:e58. [quiz e75].
30. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
31. Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando) 2008, 22:262-273.
32. McTaggart S.J., Atkinson K. Mesenchymal stem cells: immunobiology and therapeutic potential in kidney disease. Nephrology (Carlton) 2007, 12:44-52.
33. Dexter T.M. Stromal cell associated haemopoiesis. J Cell Physiol 1982, 1:87-94.
34. Tavassoli M., Friedenstein A. Hemopoietic stromal microenvironment. Am J Hematol 1983, 15:195-203.
35. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
36. Abdi R., Fiorina P., Adra C.N., Atkinson M., Sayegh M.H. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008, 57:1759-1767.
37. Devine S.M., Bartholomew A.M., Mahmud N., et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001, 29:244-255.
38. Makino S., Fukuda K., Miyoshi S., et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999, 103:697-705.
39. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105:93-98.
40. Wang G., Bunnell B.A., Painter R.G., et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci USA 2005, 102:186-191.
41. Spees J.L., Olson S.D., Ylostalo J., et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci USA 2003, 100:2397-2402.
42. Sanchez-Ramos J., Song S., Cardozo-Pelaez F., et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000, 164:247-256.
43. Woodbury D., Schwarz E.J., Prockop D.J., Black I.B. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000, 61:364-370.
44. Schwartz R.E., Reyes M., Koodie L., et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002, 109:1291-1302.
45. Sato Y., Araki H., Kato J., et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005, 106:756-763.
46. Moriscot C., de Fraipont F., Richard M.J., et al. Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells 2005, 23:594-603.
47. Davani B., Ikonomou L., Raaka B.M., et al. Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 2007, 25:3215-3222.
48. Tang D.Q., Cao L.Z., Burkhardt B.R., et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 2004, 53:1721-1732.
49. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
50. Prockop D.J. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther 2007, 82:241-243.
51. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007, 25:2896-2902.
52. Seeberger K.L., Dufour J.M., Shapiro A.M., Lakey J.R., Rajotte R.V., Korbutt G.S. Expansion of mesenchymal stem cells from human pancreatic ductal epithelium. Lab Invest 2006, 86:141-153.
53. Young H.E., Mancini M.L., Wright R.P., et al. Mesenchymal stem cells reside within the connective tissues of many organs. Dev Dyn 1995, 202:137-144.
54. Sordi V., Malosio M.L., Marchesi F., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
55. Fox J.M., Chamberlain G., Ashton B.A., Middleton J. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 2007, 137:491-502.
56. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084.
57. Caplan A.I. Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217:318-324.
58. Lee R.H., Seo M.J., Reger R.L., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006, 103:17438-17443.
59. Wu Y., Chen L., Scott P.G., Tredget E.E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007, 25:2648-2659.
60. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008, 3:e1886.
61. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
62. Klyushnenkova E., Mosca J.D., Zernetkina V., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005, 12:47-57.
63. Stagg J., Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol 2007, 180:45-66.
64. Noel D., Djouad F., Bouffi C., Mrugala D., Jorgensen C. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007, 48:1283-1289.
65. Ramasamy R., Fazekasova H., Lam E.W., Soeiro I., Lombardi G., Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007, 83:71-76.
66. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
67. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009, 37:1445-1453.
68. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
69. Glennie S., Soeiro I., Dyson P.J., Lam E.W., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
70. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
71. Maccario R., Podesta M., Moretta A., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
72. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
73. Corcione A., Benvenuto F., Ferretti E., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
74. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006, 177:2080-2087.
75. Jiang X.X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
76. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
77. Battiwalla M., Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009, 11:503-515.
78. Tolar J., Le Blanc K., Keating A., Blazar B.R. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010, 28:1446-1455.
79. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
80. Taupin P. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr Opin Investig Drugs 2006, 7:473-481.
81. Chen S.L., Fang W.W., Ye F., et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004, 94:92-95.
82. Sueblinvong V., Weiss D.J. Cell therapy approaches for lung diseases: current status. Curr Opin Pharmacol 2009, 9:268-273.
83. Mazzini L., Mareschi K., Ferrero I., et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res 2006, 28:523-526.
84. Bang O.Y., Lee J.S., Lee P.H., Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005, 57:874-882.
85. Yoshikawa T., Mitsuno H., Nonaka I., et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 2008, 121:860-877.
86. Christopeit M., Schendel M., Foll J., Muller L.P., Keysser G., Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008, 22:1062-1064.
87. Liang J., Zhang H., Hua B., et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 69:1423-1429.
88. Giordano A., Galderisi U., Marino I.R. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007, 211:27-35.
89. Lu Y., Jin X., Chen Y., et al. Mesenchymal stem cells protect islets from hypoxia/reoxygenation-induced injury. Cell Biochem Funct 2010, 28:637-643.
90. Park K.S., Kim Y.S., Kim J.H., et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation 2010, 89:509-517.
91. Jung E.J., Kim S.C., Wee Y.M., et al. Bone marrow-derived mesenchymal stromal cells support rat pancreatic islet survival and insulin secretory function in vitro. Cytotherapy 2011, 13:19-29.
92. Urban V.S., Kiss J., Kovacs J., et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008, 26:244-253.
93. Ding Y., Xu D., Feng G., Bushell A., Muschel R.J., Wood K.J. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 2009, 58:1797-1806.
94. Solari M.G., Srinivasan S., Boumaza I., et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 2009, 32:116-124.
95. Jurewicz M., Yang S., Augello A., et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 2010, 59:3139-3147.
96. Fiorina P., Jurewicz M., Augello A., et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009, 183:993-1004.
97. Ito T., Itakura S., Todorov I., et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation 2010, 89:1438-1445.
98. Berman D.M., Willman M.A., Han D., et al. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes 2010, 59:2558-2568.
99. Itakura S., Asari S., Rawson J., et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007, 7:336-346.
100. Baertschiger R.M., Bosco D., Morel P., et al. Mesenchymal stem cells derived from human exocrine pancreas express transcription factors implicated in beta-cell development. Pancreas 2008, 37:75-84.
101. Carlotti F., Zaldumbide A., Loomans C.J., et al. Isolated human islets contain a distinct population of mesenchymal stem cells. Islets 2010, 2:164-173.